Ben Matone Email Address

Senior Director, Investor Relations

Develops DNA based immunotherapies targeting cancers and infectious diseases. Best-in-class T cell responses have also generated clinically relevant efficacy.

Ben is Head of Investor Relations at Inovio Pharmaceuticals (NASDAQ: INO). For the past four+ years, Ben has grown the company's equity research coverage and institutional ownership, while also improving its corporate image and exposure on Wall Street; all of which has supported the company's growth from a sub $200M to $2BN market cap company. Ben has over 14 years of IR and equity capital market experience, all tailored to the Biotechnology and Specialty Pharma sectors, where he spent 11 of those years on the advisory services/capital market intelligence side. Prior to joining INOVIO, Ben managed a successful advisory services consultancy based in New York, exclusive to life science companies, where he provided business development and investor relations expertise to private and public biotechnology companies. Prior to this, Ben had spent nine years at NASDAQ as Director of the biotechnology corporate solutions group. Ben has completed graduate course work towards earning an M.S. in Finance from The Pennsylvania State University and holds a B.S. in Finance from the University of Rhode Island - College of Business. Experience & Skills: Capital Markets Analysis Corporate Development Corporate Communications Crisis Management Equity Capital Markets Financial Modeling & Valuations IPOs Investor Relations Venture Capital/Private Equity